UnknownPhase 1

To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

Iran40 participantsStarted 2006-08

Plain-language summary

Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Uveitic CME * Uveitic CME refractory to routine treatment * Vision better than 5/200 and worse than 20/50 Exclusion Criteria: * Mono- Ocular patients * History of vitrectomy * Glaucoma or ocular hypertension * History of other retinal disease that can cause macular edema * Pregnancy * Significant media opacity * Vision better than 20/50

What they're measuring

Resorbed CME in OCT

Timeframe: every 3 month

Resorbed CME in clinical examination

Timeframe: Every 3 month

Trial details

NCT IDNCT00371111

SponsorShahid Beheshti University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-05

View on ClinicalTrials.gov More Resistant Cystoid Macular Edema trials